My NCBISign In
Vorinostat in solid and hematologic malignancies
David Siegel, Mohamad Hussein, Chandra Belani, Francisco Robert, Evanthia Galanis, Victoria M Richon, José Garcia-Vargas, Cesar Sanz-Rodriguez, Syed Rizvi
J Hematol Oncol. 2009; 2: 31. Published online 2009 July 27. doi: 10.1186/1756-8722-2-31
PMCID:
PMC2731787
Abstract Full Text PDF–1.0M

Is Cited by the Following 9 Articles in this Archive:

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
Rive Sarfstein, Ilan Bruchim, Ami Fishman, Haim Werner
PLoS One. 2011; 6(9): e24468. Published online 2011 September 8. doi: 10.1371/journal.pone.0024468
PMCID:
PMC3169604
Abstract Full Text PDF–1.6M
Cancer cells’ epigenetic composition and predisposition to histone deacetylase inhibitor sensitization
Narasimharao Nalabothula, France Carrier
Epigenomics. Author manuscript; available in PMC 2012 February 1.
Published in final edited form as: Epigenomics. 2011 April 1; 3(2): 145–155.
PMCID:
PMC3129700
Abstract Full Text PDF–1.4M
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K Ted Thurn, Scott Thomas, Amy Moore, Pamela N Munster
Future Oncol. Author manuscript; available in PMC 2011 December 1.
Published in final edited form as: Future Oncol. 2011 February; 7(2): 263–283. doi: 10.2217/fon.11.2
PMCID:
PMC3127396
Abstract Full Text PDF–934K
Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin
Shaohong Jiang, Xudong Ma, Yiqun Huang, Yunlu Xu, Ruiji Zheng, Jen-Wei Chiao
J Hematol Oncol. 2010; 3: 48. Published online 2010 November 29. doi: 10.1186/1756-8722-3-48
PMCID:
PMC3009608
Abstract Full Text PDF–652K
Epigenomics in cancer management
Fabricio F Costa
Cancer Manag Res. 2010; 2: 255–265. Published online 2010 October 27. doi: 10.2147/CMR.S7280
PMCID:
PMC3004578
Abstract Full Text PDF–222K
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
Leigh Ellis, Roberto Pili
Pharmaceuticals (Basel) Author manuscript; available in PMC 2010 December 10.
Published in final edited form as: Pharmaceuticals (Basel). 2010 August 1; 3(8): 2411–2469. doi: 10.3390/ph3082441
PMCID:
PMC3000686
Abstract Full Text PDF–375K
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Xiongpeng Zhu, Yuehua Ma, Delong Liu
J Hematol Oncol. 2010; 3: 17. Published online 2010 April 23. doi: 10.1186/1756-8722-3-17
PMCID:
PMC2880983
Abstract Full Text PDF–788K
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
Pimjai Niparuck, Ladda Sorakhunpipitkul, Vichai Atichartakarn, Suporn Chuncharunee, Artit Ungkanont, Pantep Aungchaisuksiri, Teeraya Puavilai, Saengsuree Jootar
J Hematol Oncol. 2010; 3: 1. Published online 2010 January 5. doi: 10.1186/1756-8722-3-1
PMCID:
PMC2828404
Abstract Full Text PDF–172K
The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer
Fulvio Lonardo, Xiaohua Li, Alexander Kaplun, Ayman Soubani, Seema Sethi, Shirish Gadgeel, Shijie Sheng
Curr Pharm Des. Author manuscript; available in PMC 2010 July 22.
Published in final edited form as: Curr Pharm Des. 2010; 16(16): 1877–1881.
PMCID:
PMC2908495
Abstract Full Text PDF–271K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk